Axogen, Inc. (AXGN) Stock
Fundamentals
Recent news

AxoGen Q2 Earnings Call Highlights
AxoGen Q2 Earnings Call Highlights
AXGN

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AXGN

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AXGN

AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) Q1 Earnings Lag Estimates
AXGN
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.02 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

AxoGen Q2 Earnings Call Highlights
AxoGen Q2 Earnings Call Highlights
AXGN

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AXGN

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AXGN

AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) Q1 Earnings Lag Estimates
AXGN

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AXGN

AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
AXGN

Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
AXGN

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
AXGN

AxoGen (AXGN) Q4 Earnings Miss Estimates
AxoGen (AXGN) Q4 Earnings Miss Estimates
AXGN

HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
AXGN
About Axogen, Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael D. Dale | President, CEO & Director | 1960 |
| Ms. Lindsey Hartley CPA | Chief Financial Officer | — |
| Mr. Harold D. Tamayo M.B.A. | Vice President of Finance & Investor Relations | — |
| Dr. Ivica Ducic M.D., Ph.D. | Chief Medical Officer | — |
| Ms. Doris Quackenbush | Chief Revenue Officer | — |
| Mr. Rick Ditto | Vice President of Global Health Economics, Reimbursement & Policy | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
5 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.2 | -5.1 | -37.1 | -0.6 | ||||||||
| 2022 | -12.7 | +8.6 | -12.4 | -11.3 | +28.9 | -11.8 | +14.1 | -3.9 | +27.1 | -5.7 | -2.0 | -9.5 |
| 2023 | -4.1 | -11.2 | +15.8 | -4.0 | -8.3 | +5.7 | -2.4 | -26.4 | -20.6 | -24.8 | +81.4 | -0.7 |
| 2024 | +39.9 | +8.3 | -24.5 | -19.4 | +4.1 | +6.2 | +13.9 | +61.2 | +6.6 | -2.2 | -0.4 | +13.2 |
| 2025 | +11.0 | +11.7 | -4.1 | -8.6 | -33.9 | -1.1 | +19.4 | +27.4 | +13.6 | +24.3 | +23.2 | +14.7 |
| 2026 | +12.4 | -9.4 | +8.1 | +28.6 | -8.8 | +19.3 | -4.1 | +11.0 | -13.0 |



